Open AccessThe clinical and economic burden of peripheral T-cell lymphoma: a systematic literature review
Author(s) -
Ajibade Ashaye,
Heather Burnett,
Ṣẹ̀yẹ Abògúnr̀in,
H. Panchmatia,
O. Ovcinnikova,
Mehul Dalal
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-1032
Subject(s) - medicine , chop , vincristine , prednisone , peripheral t cell lymphoma , oncology , regimen , cyclophosphamide , lymphoma , rituximab , chemotherapy , immunology , immune system , t cell
Aim: To understand the burden of treatment-naive peripheral T-cell lymphoma (PTCL). Methods: A systematic literature review was conducted in November 2020 following best practice methodology. Results: Fifty-five clinical studies were included, mostly investigating cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or ‘CHOP-like’ regimens, with combination regimens showing similar effectiveness to CHOP alone. Aside from the combination of brentuximab vedotin + cyclophosphamide, doxorubicin and prednisone (A+CHP), other available treatments showed no statistically significant benefit over CHOP in terms of overall or progression-free survival in overall PTCL patients. The mean monthly cost per patient in the USA ranged from 6328 to US$9356 based on six studies. One economic evaluation demonstrated A+CHP to be a more cost-effective treatment option than CHOP. Conclusion: Further research is needed to understand the humanistic and cost impact of frontline treatment for PTCL and its specific subtypes.